The Hyperammonemia drugs in development market research report provides comprehensive information on the therapeutics under development for Hyperammonemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hyperammonemia. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hyperammonemia and features dormant and discontinued products.
GlobalData tracks six drugs in development for Hyperammonemia by six companies/universities/institutes. The top development phase for Hyperammonemia is discovery with four drugs in that stage. The Hyperammonemia pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Hyperammonemia pipeline products market are: Genfit, TenNor Therapeutics and Cycle Pharmaceuticals.
The key targets in the Hyperammonemia pipeline products market include DNA Topoisomerase IV (EC 5.99.1.3), DNA Gyrase (EC 5.99.1.3), and Glutamate Dehydrogenase 1 Mitochondrial (GLUD1 or EC 1.4.1.3).
The key mechanisms of action in the Hyperammonemia pipeline product include RNA Polymerase (EC 2.7.7.6) Inhibitor with one drug in Phase II. The Hyperammonemia pipeline products include three routes of administration with the top ROA being Intraperitoneal and two key molecule types in the Hyperammonemia pipeline products market including Small Molecule, and Gene-Modified Cell Therapy.
Hyperammonemia overview
Hyperammonemia is a metabolic condition characterized by increased levels of ammonia, a nitrogen-containing compound. This is due to N-acetylglutamate synthase deficiency. This may lead to brain injury and death. Hyperammonemia can result from various congenital and acquired conditions in which it may be the principal toxin. Hyperammonemia may also occur as a part of other disorders that involve various other metabolic abnormalities
For a complete picture of Hyperammonemia’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
